Sarepta Therapeutics | SRPT - Loan Capital


Sarepta Therapeutics reported $828.97M in Loan Capital for its fiscal quarter ending in December of 2025.





Loan Capital Change Date
Acadia Pharmaceuticals USD 0 0 Mar/2025
Agios Pharmaceuticals USD 1.06M 0 Sep/2022
Alnylam Pharmaceuticals USD 2.48B 1.44B Dec/2025
Amgen USD 50B 2.43B Dec/2025
BioCryst Pharmaceuticals USD 428.67M 234.31M Dec/2025
Biogen USD 6.29B 1.4M Sep/2025
BioMarin Pharmaceutical USD 597.18M 513K Dec/2025
Capricor Therapeutics USD 3.38M 0 Mar/2025
Daiichi Sankyo JPY 300.15B 199.41B Dec/2025
Eli Lilly USD 40.87B 5.6M Dec/2025
Esperion Therapeutics USD 457.65M 9.5M Dec/2025
Gilead Sciences USD 22.13B 6M Dec/2025
Incyte USD 30.2M 5.17M Dec/2025
Insmed USD 540.96M 1.24M Dec/2025
Ionis Pharmaceuticals USD 1.9B 1.87B Dec/2025
Moderna USD 610M 584M Dec/2025
Nektar Therapeutics USD 63.16M 44.35M Dec/2025
Neurocrine Biosciences USD 169.5M 500K Mar/2023
Novavax USD 246.3M 200K Dec/2025
Pfizer USD 57.41B 93M Sep/2025
PTC Therapeutics USD 2.03B 193.22M Dec/2025
Regeneron Pharmaceuticals USD 2.71B 720.4M Dec/2025
Roche Holding CHF 27.43B 966M Dec/2025
Sangamo BioSciences USD 0 0 Jun/2022
Sanofi EUR 13.84B 1.88B Mar/2026
Sarepta Therapeutics USD 828.97M 206.17M Dec/2025
Tectonic Therapeutic USD 43K 57K Dec/2025
Ultragenyx Pharmaceutical USD 763.74M 19.02M Sep/2025
Vertex Pharmaceuticals USD 111.4M 1.4M Mar/2025